Galleri Multi-Cancer Early Detection
A blood test that screens for 50+ cancers — controversial, expensive, and the most-debated longevity diagnostic of 2026.
A blood test screening for 50+ cancers — the most-debated longevity diagnostic of 2026.
Galleri (made by GRAIL, an Illumina spinout) detects circulating tumor DNA across 50+ cancer types from a single blood draw, and predicts the tissue of origin if cancer signal is found. It's the closest thing to a "screening for everything" blood test that exists.
The data behind it is real but nuanced: in published studies it has a high specificity (low false-positive rate, ~99.5%), moderate sensitivity (catches roughly 50% of stage-I cancers, higher at later stages), and the tissue-of-origin prediction is right ~88% of the time. For a screening test, that's genuinely good. For a definitive diagnostic, that's incomplete.
Who should consider it: people over 50, anyone with significant family cancer history, and longevity-focused buyers with the budget who want an additional screening layer beyond colonoscopy/mammogram/etc. Who shouldn't: anyone prone to over-treating uncertain findings (a positive Galleri triggers a follow-up imaging cascade that's itself non-trivial).
Buyers over 50, those with family cancer history, longevity-focused spenders adding a screening layer to standard surveillance.
You're under 40 with no family history (false-positive math is unfavorable), or you can't afford the follow-up imaging if it triggers.